ArticleOncotarget2015

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.

Begoña Martin-Castillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.